Newsroom press releases

11/11/24 - 7:38

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)

Products Molecular

05/11/24 - 16:27

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)

Financial Data

27/09/24 - 7:35

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)

Products Molecular

09/09/24 - 13:11

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)

Products Immunodiagnostic

05/09/24 - 11:17

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)

Other

04/09/24 - 11:36

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)

Other

29/07/24 - 17:35

Diasorin: Publication of the documents for the Shareholders' Meeting scheduled on September 4, 2024 (135.08 KB)

Other

29/07/24 - 15:55

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)

Financial Data

16/07/24 - 8:31

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)

Products Molecular

05/06/24 - 5:07

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)

Products Molecular

16/05/24 - 19:56

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)

Products Molecular

10/05/24 - 17:54

Restart of the buyback program (108.54 KB)

Other

10/05/24 - 15:21

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)

Financial Data

24/04/24 - 15:38

Shareholders' Meeting 2024 (159.72 KB)

Other

16/04/24 - 8:20

Communication on total amount of voting rights (135.47 KB)

Other

04/04/24 - 9:34

DiaSorin S.p.A.- Update 2024 Annual Calendar of Corporate Events (103.76 KB)

Financial Disclosures , Other

15/03/24 - 17:14

Diasorin: Publication of the documents for the Ordinary Shareholders' Meeting scheduled on April 24, 2024 (135.35 KB)

Other

15/03/24 - 13:35

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)

Financial Data

13/03/24 - 10:23

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)

Products Molecular

03/03/24 - 19:32

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)

Products Molecular

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)

Products Immunodiagnostic

18/01/24 - 12:30

2024 Annual Calendar of Corporate Events (115.8 KB)

Other